Aquestive Therapeutics, Inc. (AQST): Price and Financial Metrics
AQST Price/Volume Stats
| Current price | $4.42 | 52-week high | $6.23 |
| Prev. close | $4.50 | 52-week low | $1.15 |
| Day low | $4.42 | Volume | 15,553 |
| Day high | $4.42 | Avg. volume | 2,171,530 |
| 50-day MA | $4.00 | Dividend yield | N/A |
| 200-day MA | $2.41 | Market Cap | 323.99M |
AQST Stock Price Chart Interactive Chart >
Aquestive Therapeutics, Inc. (AQST) Company Bio
Aquestive Therapeutics, Inc. operates as a specialty pharmaceutical company that specializes in the drug delivery technology. The company offers PharmFilm, a drug delivery platform/pharmaceutical dosage form that delivers existing prescription products directly to the bloodstream. It develops, manufactures, and commercializes pharmaceutical films, individual film doses, and finished products for patients, physicians, and caregivers. Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx Inc. and changed its name to Aquestive Therapeutics, Inc. in November 2017. The company was founded in 2000 and is based in Warren, New Jersey.
Latest AQST News From Around the Web
Below are the latest news stories about AQUESTIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate AQST as an investment opportunity.
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive TherapeuticsAmphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog. |
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024. |
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year. |
Best Momentum Stock to Buy for December 7thAQST and VVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 7, 2023. |
Syros (SYRS) Rises on Upbeat Initial Study Data on TamibaroteneSyros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia. |
AQST Price Returns
| 1-mo | -1.89% |
| 3-mo | 81.15% |
| 6-mo | 187.01% |
| 1-year | 220.29% |
| 3-year | 12.76% |
| 5-year | -29.73% |
| YTD | 118.81% |
| 2023 | 123.92% |
| 2022 | -76.81% |
| 2021 | -27.29% |
| 2020 | -8.08% |
| 2019 | -7.62% |
Continue Researching AQST
Want to see what other sources are saying about Aquestive Therapeutics Inc's financials and stock price? Try the links below:Aquestive Therapeutics Inc (AQST) Stock Price | Nasdaq
Aquestive Therapeutics Inc (AQST) Stock Quote, History and News - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...